Publications
Scientific Reports — February 15, 2024
A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration
The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic. A new study by Leyden Labs, published in Nature’s Scientific Reports, shows that the CR9114 antibody can protect intranasally at low dosages against H5N1 in vivo.
Journal of Epidemiology — February 04, 2023
SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.
A new article from Leyden Labs has been published in the European Journal of Epidemiology, titled "SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.”
Frontiers in Virology — November 02, 2022
The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection
Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and structural insights of neutralizing antibodies to guide viral vaccine design.
Infectious Diseases & Therapy — October 30, 2022
Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community
A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
© Leyden Labs, 2023 | Privacy Statement | Design by Ape to Zebra
